Imugene Capital Raising Presentation

1 Release authorised by the Managing Director and Chief Executive Officer Imugene Limited Innovation in Cancer Treatment Capital Raising Presentation July 2026 ASX:IMU 2 Disclaimer This presentation (Presentation) has been prepared by Imugene Limited (ASX: IMU) (Company) in connection with a two tranche n on- underwritten placement (Placement) of new fully paid ordinary shares in the Company (Offer). The following notices and disclaimers apply to this Presentation and you are therefore advised to read this carefully before reading or making use of this Presentation or any information contained in this Presentation. By accepting, accessing or reviewing this Present ation, you acknowledge and agree to the terms set out in this disclaimer. The information in this Presentation does not constitute personal investment advice. The presentation is not intended to be c omprehensive or provide all information required by investors to make an informed decision on any investment in Imugene Limited (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any p articular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt wi th in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, e xpress or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or f airness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that in formation or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable fo r any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any doc ument supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damage s are expressly disclaimed. Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change. The material in this Presentation contains certain forecasts and forward -looking information which can generally be identified b y the use of words such as “will”, “may”, “should”, “could”, “likely”, “consider”, “ongoing”, “anticipate”, “estimate”, “expect”, “project ”, “predict”, “propose”, “intend”, “plan”, “believe”, “target”, “forecast”, “goal”, “objective”, “aim”, “seek” and other similar expressions, includin g (without limitation) regarding possible or assumed future performance or potential growth of the Company and the timetable and outcome of the Plac ement and the use of the proceeds thereof . Such information is not a guarantee of future performance and involves known and unknown ri sks and uncertainties, as well as other factors, many of which are beyond the control of the Company. Actual results and developments may differ materially from those expressed or implied by these forward-looking statements depending on a variety of factors. No representat ion or warranty, expressed or implied, is made or given by or on behalf of the Company, any of the Company’s directors, or any other person as to the accuracy or completeness or fairness of the information or opinions contained in this Presentation and no responsibility or l iability is accepted by any of them for such information or opinions or for any errors, omissions, misstatements, negligent or otherwise, or for any communication written or otherwise, contained or referred to in this presentation. Investors are cautioned not to place undue reliance on such statements. The Company undertakes no obligation to update publicly or release any revisions to these forward -looking statements. Accordingly, neither the Company nor any of the Company’s directors, officers, employees, advisers, associated persons or subsidiary undertakings shal l be liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon the statement or as a result of any admission in, or any document supplied with, this presentation or by any future communications in connection with such docume nts and any such liabilities are expressly disclaimed. This Presentation is not and should not be considered an offer or invitation for subscription or purchase of, or a recommendatio n in relation to, securities in the Company or any other financial products and neither this Presentation nor anything contained in it shall fo rm the basis of any contract or commitment. This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law or any other law and will not be lodged with the Australian Securities and Investments Commission. The distribution of this Presentation (including an electronic copy) in jurisdictions outside Australia may be restricted by law and any such restrictions should be observed. Any failure to comply with such restrictions may constitute a violation of applicable securi ties laws. This Presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United State s or to any person that is, or is acting for the account or benefit of, any “U.S. person” (as defined in Regulation S under the US Securities Act of 1933 , as amended). International offer restrictions - This document does not constitute an offer to sell, or a solicitation of an offer to buy, sec urities in the United States or any other jurisdiction in which it would be unlawful. In particular, the New Shares have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subj ect to, the registration requirements of the US Securities Act and applicable US state securities laws. The distribution of this presenta tion in jurisdictions outside Australia may be restricted by law and any such restrictions should be observed. Bell Potter Securities Limited (ACN 006 390 772) is acting as lead manager to the Offer. The Lead Manager is acting for and providing services to the Company in relation to the Placement and will not be acting for or providing services to the Company’s shareholders or creditors. The Lead Manager have been engaged solely as independent contractors and are acting solely in a contractual relationship on an arm’s length basis with the Company. The engagement of the Lead Manager by the Company is not intended to create any agency, fiduciary or other relationship between the Lead Manager and the Company’s shareholders or creditors. To the maximum extent permitted by law, the Lead Manager and their respective related bodies corporate and affiliates, and each of their respective officers, directors, employees, agents and advisers (each a Limited Party): (i) expressly exclude and disclaim all duties, responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentatio n, including for any indirect, consequential, special or economic loss or damage (including, without limitation, any loss of profit or anticipated profit, fines or penalties, loss of business or anticipated savings, loss of use, business interruption or loss of goodwill, bargain or opportuni ties); (ii) disclaim any obligations or undertaking to release any updates or revision to the information in this Presentation to reflect any change i n expectations or assumptions; and (iii) do not make any representation or warranty, express or implied, as to the reasonableness, fairness, ac curacy, reliability or completeness of the information in this Presentation or that this Presentation contains all material information about the Co mpany, the Offer or that a prospective investor or purchaser may require in evaluating a possible investment in the Company or acquisition of sha res in the Company, or likelihood of fulfilment of any forward -looking statement, forecast, prospects, returns or any event or results expr essed or implied in any forward-looking statement or any information in this Presentation. The Lead Manager and their respective Limited Parties have not independently verified the information in this Presentation and take no responsibility for any part of this Presentation. They make no recommendations as to whether you or your related parties shou ld participate in the Offer, nor do they make any representations or warranties to you concerning the Offer. The Lead Manager nor any of their respective Limited Parties has authorised, permitted or caused the issue, submission, dispatch or provision of this Presentation and they do not make or purport to make any statement in this Presentation and there is no statement in this Presentation which is based on any state ment by any of them (except for references to the Lead Manager’s name). You represent, warrant and agree that you have not relied on any sta tements made by the Lead Manager or their respective Limited Parties. You undertake that you will not seek to sue or hold the Lead Manager or their respective Limited Parties liable in any respect in connection with this Presentation or the Offer (to the maximum extent per mitted by law). The Lead Manager and their respective affiliates and related bodies corporate (collectively, LM Group and each a LM Group Member) are full service financial institutions engaged in various activities, which may include (but are not limited to) underwriting, tradin g, financing, corporate advisory, financial advisory, investment management, investment research, principal investment, hedging, market making, broke rage and other financial and non-financial activities and services including for which they have received or may receive customary fees and exp enses or other transaction consideration. In the course of these activities, members of the LM Group may at any time for their own account and for the accounts of their clients make or hold investments in equity securities or other financial products of the Company or its rel ated entities and receive customary fees and expenses or other transaction consideration in respect of such activities. The Lead Manager may receive fees for acting in their capacity as lead managers to the Offer. You acknowledge and agree that the determination of eligibility of investors for the purposes of the Offer is determined by r eference to a number of matters, including legal and regulatory requirements, logistical and registry constraints and the discretion of the Company and the Lead Manager. Each of the Company, the Lead Manager and their respective Limited Parties disclaim any duty or liability (including for negligence) in respect of the exercise or otherwise of that discretion, to the maximum extent permitted by law. None of the Lead Manager nor any of their respective Limited Parties have any obligation to update the statements in this Presentation. For the avoidance of doubt, the Offer is not underwritten. 3 Imugene is a clinical stage cancer company developing an allogeneic CAR-T for blood cancer 4 Executive Summary Azer-cel is an off-the-shelf CAR T therapy with compelling efficacy, regulatory clarity, and multiple capital-efficient paths to market Overview & Market Opportunity Lead program azer-cel: off-the-shelf (allogeneic) Designed for immediate availability, scalable manufacturing and broader patient access compared with autologous therapies. Large and growing market CD19 CAR T therapies represent a multi-billion- dollar global opportunity in B-cell malignancies, with significant unmet need in r/r NHL and other blood cancers. Experienced leadership team Deep expertise in cell therapy, drug development and commercialisation with a proven track record of execution. Clinical Validation 18 Complete Responses 19 Partial Responses Strong clinical foundation • 82% ORR (14/17) in 3L+ DLBCL post-CAR T relapse (Cohort 1) • 100% ORR in CLL/FL/WM, 83% in MZL, CAR T naive (Cohort 2) • 100% ORR, 2/2 CR in FL and MCL Concurrent BTKi (Cohort 3) Manageable safety profile • CRS primarily low grade; no treatment-related Grade 4/5 neurotoxicity to date. Regulatory progress • FDA Type C Meeting completed – alignment on dose regimen and CMC pivotal study readiness • FDA Fast Track Designation for DLBCL, CLL/SLL and MZL Upcoming Catalysts Partnerships & market expansion • Advanced discussions with a major global pharma company re: strategic collaboration • Ongoing partnering / out-licensing discussions for azer-cel Multiple clinical data readouts • BTKi combination study underway; additional patient readout 2H 2026 • Further readouts across CAR-T naive/niche cohorts; ASCO, EHA, ASH 2026/2027 Regulatory pathway • FDA engagement to support accelerated approval and fast to market strategy • Pursuing FDA RMAT/Breakthrough designation CAPITAL RAISING ~A$11.1 million (Two-tranche placement) USE OF FUNDS • Advance the azer-cel pivotal program and regulatory pathway • Expand clinical development and combination studies • Strengthen manufacturing scale-up and operational execution To fund the next stage of azer-cel development and strategic opportunities as we advance discussions with a major pharmaceutical company. 5 Azer-cel: Development Timeline Key milestones achieved since March 2026 capital raising and approaching Pharma collaboration window PHARMA COLLABORATION WINDOW ACHIEVED MILESTONES UPCOMING MILESTONES Fast Track Designation DLBCL 82% ORR R/R DLBCL Positive FDA Type C Meeting 83% ORR CAR-T Naïve 100% ORR CLL 80% MZL Jun 2026 Concurrent BTKi Cohort FPI + ASCO Oral Presentation Phase 1b Data CAR-T naïve + BTKi Conferences; ASH, EHA, ASCO FDA regulatory potential for designation RMAT/ breakthrough Potential Pharma Collaboration Pivotal Study Initiation of manufacturing CDMO Imugene is advancing azer-cel toward pivotal readiness, with key clinical data, regulatory engagement and manufacturing preparation underpinning the program's next stage of growth. Timelines are indicative and subject to regulatory approvals, patient recruitment, and clinical outcomes. Mar 25 Sep 25 Dec 25 Mar 26 May 26 2H 2026 CY27 Jun 26 Fast Track Designation CLL/SLL and MZL FDA Re-engagement Concurrent BTKi Cohort Data Update Complete Response Concurrent BTKi First 2 Patients 6 Experienced Leadership Team and BoD has brought FDA-Approved Drugs to Market Executive Management Team Board of Directors Leslie Chong Chief Executive Officer & Managing Director John Byon, MD, PhD Chief Medical Officer Ursula McCurry Chief Clinical Operations Officer Darren Keamy Chief Financial Officer & Company Secretary Paul Hopper Executive Chairman and Founder Dr. Jakob Dupont, MD Non-Executive Director Kim Drapkin Non-Executive Director Dr. Lesley Russell Non-Executive Director Leslie Chong CEO & Managing Director 7 7 Azer-cel Overview 8 How is Imugene different? Allogeneic vs Autologous CAR-T Allogeneic CAR-T Cell Therapy is significantly differentiated from approved Autologous CAR-T therapies on cost and wait times 1Science Direct publication 17 April 2025; Sequential CD19-20 CAR-T cell therapy for refractory/relapsed diffuse large B-cell lymphoma Autologous Allogeneic Overview • Autologous CAR-T cells are made from the patient’s own T-cells • Highly personalised (one to one therapy) • ~60% relapse off of CD19 auto CAR-T1 • Dose for multiple patients from a single healthy donor (one batch to many) Cost • High manufacturing costs • Greater risk of manufacturing issues due to single production runs • Highly scalable manufacturing with potential attractive gross margins (lower COGS given ‘one batch-to-many’ approach) Wait time • Long process and wait time of around 4-6 weeks • No wait time Single vs multi dose • Single does, can not be re-dosed with autologous CAR-T • Potential for multi dose Safety • Acceptable safety profile • Good safety profile Access • Limited access – major centres only given 1-1 nature • Opens up new centres / regional markets for patients • T-Cells extracted from patient’s blood • T-cells reprogrammed into CD19 CAR-T cells (19-42 days wait) • Modified T cells are multiplied in large numbers and infused back into the patient • Reprogrammed T-cells targets and destroys cancer cells 1. Collection from cancer patient 3. Infusion back into patient 2. Genetic Modification Autologous Allogeneic 1. Collection from healthy donor 3. Infusion into multiple patients 2. Genetic Modification • T-Cells extracted from the blood of a HEALTHY UNIVERSAL donor • T cells reprogrammed into CD19 CAR-T cells • Modified T cells are multiplied in large numbers and available for MANY patients • Reprogrammed T-cells targets and destroys cancer cells 9 1https://ascopost.com/news/november-2023/novel-strategy-may-improve-outcomes-in-patients-with-treatment-resistant-dlbcl/ Introducing azer-cel Imugene’s potential first-in-class, off-the-shelf Allogeneic CAR-T Cell Therapy “Off-the-shelf” CD19 Allogeneic CAR-T Addresses high and growing unmet need in blood cancers Current Phase 1b study enrolling at leading US and Australian centres Fast Track Designation received for DLBCL, allows for greater FDA engagement and priority review. FDA support for registrational and manufacturing pathway received Nov 2025 1 3 2 4 1. Collection from healthy donor 3. Infusion into multiple patients 2. Genetic Modification 10 Azer-cel Phase 1b Study CAR-T Relapsed DLBCLCohort 1 • First patient dosed in April, 2024 (n=22) • 82% ORR (14/17) in 3L+ DLBCL, including heavily pre-treated patients • ~50% failed bispecific therapies and prior autologous CAR-T • Compares favorably to approved autologous CAR-T therapies in earlier lines CAR-T Naïve Niche IndicationsCohort 2 • First patient dosed in July, 2025 (n=26 ongoing) • CAR-T Naïve patient population with rare / niche indications potentially enabling smaller registrational studies • 100% Overall Response in CLL, FL, WM • 83% Overall Response Rate in MZL Concurrent BTKi CombinationCohort 3 • First Patient dosed, 28 May 2026 (n=4 ongoing) • 2 CRs from FL and MCL Patients (2/2 Evaluable, 100% ORR) • Bruton Tyrosine Kinase inhibitor (BTKi) combination cohort leveraging a >$12bn therapeutic class • Provides optionality across registrational, commercial and Business Development strategies • Advanced strategic collaboration discussions ongoing with Big Pharma Positive FDA Type C meeting in Nov 2025 confirmed regulatory and manufacturing pathway Next Key Milestone: Data Update August 2026 Next Key Milestone: Data Update Q3 2026 Dose expansion is currently enrolling across CAR-T relapsed, CAR-T naïve and concurrent BTKi combination cohorts 11 1. SEER 2020 Estimate; numbers of potential patients 2. NCCN guidelines, ASH, Peer-reviewed literature & CAR-T clinical trials; Assumes 3L+ for DLBCL and 2L+3L for all other cancers 3. TAM: total addressable market is total number of treatable patients x price (assumes $400,000/dose) at 100% market share. TAM is a potential market only and depends upon regulatory approval, successful commercialization, market share and timing Azer-cel: Commercial Opportunity may leverage a De-risked Regulatory Roadmap • Azer-cel Targets High-Need Indications for Single-Arm Registrational/Pivotal Trial: Ideal for pursuing accelerated approval without comparators. • Prioritizing Fast-to-Market Opportunities: azer-cel is positioned to leverage other high-need indications for potential fast-to-market entry, using DLBCL to support broader development. • Promising Niche Indications with Strong Commercial and Regulatory Potential • A $2B+ Market Built on Strategically Chosen, Comparator-Free Indications: azer-cel’s commercial roadmap is to prioritize rapid regulatory path with capital–efficient development for fast to market entry. PCNSL = Primary Central Nervous System Lymphoma (≥1 prior line of therapy containing high-dose MTX) CLL/SLL = Chronic or Small Lymphocytic Leukemia (Prior BTKi and BCL2i or only prior BTKi and high-risk features) DLBCL = Diffuse Large B-cell Lymphoma (≥1 prior line of therapy, including anti-CD20 + anthracycline) MZL = Marginal Zone Lymphoma (≥2L of prior therapy, including anti-CD20 chemoimmunotherapy) WM = Waldenstrom’s Macroglobulinemia (≥2L of prior therapy, including anti-CD20 chemoimmunotherapy) US INCIDENCE 1 ELIGIBLE FOR CAR-T 2 AZER CEL MARKET OPPORTUNITY 3 Azer-cel Commercialization Opportunity $3bn+ p.a. US potential market opportunity in rare & niche indications and 3L+ DLBCL DLBCL/HGBCL $1.4B MZL $480M PCNSL $360M WM $120M CLL/SLL $680M DLBCL/HGBCL 3600 CLL/SLL 1700 PCNSL 900 WM 300 MZL 1200 DLBCL/HGBCL 30,000 CLL/SLL 20,000 PCNSL 1500 WM 1000 MZL 4500 12 12 Azer-cel Phase 1b Study 13 Compelling Cohort 1 Phase 1b data in DLBCL to date 82% Overall Response Rate in Relapsed/Refractory (R/R) DLBCL 57% 79% 81% 82% Overall Response rate February August September December Number of Patients 4/7 11/14 13/16 14/17 Best Durability (time of response) >10 months on going >15 months on going >17 months on going >19 months on going Evaluable Patients Treatment DLBCL Lymphodepletion (LD)3 +azer-cel +Interleukin-2 (IL-2) Key Takeaways 2025 American Society Hematology (ASH) Oral Presentation • Phase 1b trial continues to enrol patients across leading cancer centers in the US and Australia • Responses were seen in patients who failed multiple prior treatments, including autologous CAR-T therapy with approximately 50% additionally failing bispecific therapies • Highly encouraging data in patient population with significant unmet need o 14 out of 17 patients have achieved ORR of 82%, defined as either CR or PR o Excellent CAR-T expansion and evidence of persistence > 90 days; o Best durability of response as of June 2026, 26+ months and ongoing • Good Safety profile / consistent with autologous CAR-T therapies o Well-tolerated with no Grade 3 or higher CRS1 or ICANS2 • Received Fast Track Designation for DLBCL CR rate assessment requires longer patient follow-up: for approved, autologous CD19 CAR-T products, the average time to best response is 2-3 months with some patients taking up to 6 months to achieve their best response 1CRS: Cytokine release syndrome 2ICANS: Immune Effector Cell-Associated Neurotoxicity Syndrome 3Lymphodepletion(LD)/chemotherapy: Aug Cy: Flu 30mg/m2 x 3d, Cy 750mg/m2 x 3d Cohort 1 of the Phase 1b study evaluates azer-cel in heavily pre-treated 3L+ patients with R/R DLBCL, including patients who have failed prior autologous CAR-T therapy 14 Azer-cel compared to existing Approved Auto CAR-T Therapies 1Company announcements and FDA.gov 2Initial response at D28 of PR, which improved to CR at later date. For approved, autologous CD19 CAR-T products, the average time to best response is 2-3 months. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.Dong, Ning et al.Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, Volume 29, Issue 6, 349.e1 - 349.e8 3Azer-cel Complete Response rate and median DoR can not yet be accurately determined as trial and patients are ongoing Azer-cel is comparable to approved Auto CAR-Ts for treatment of DLBCL 2L+ of therapy1 *CR % may vary with ongoing enrolment and time to best response Product azer-cel allo CAR-T Yescarta (Axi-cel) Kymriah (Liso-cel) Breyanzi (Tisa-cel) Indication Adult r/r DLBCL 3L+ therapy Adult r/r DLBCL ≥2 prior lines Adult r/r DLBCL ≥2 prior lines Adult r/r DLBCL ≥2 prior lines Complete response (CR) rate at day 602 45%-60%* 54% 40% 53% Median Durability of Response3 (DoR) 26+ months and ongoing ~11 months ~10.3 months ~16.7 months 82% 74% 73% 52%Overall Response Rate R/R DLBCL Initial azer-cel Ph 1b R/R DLBCL data is compelling when compared to approved Auto CAR-T treatments Despite all patients failing prior Autologous CD19 CAR-T products and approximately 50% failing bispecific therapies, azer-cel demonstrates Response Rates similar to CD19 CAR-T naïve patients. Best DoR – median not yet available 15 15 Azer-cel Clinical Development 16 Azer-cel Phase 1/1b Study Design Dose Escalation N=84 (Complete) Dose Expansion Cohorts N=50+ (Currently enrolling) 1. CAR-T Relapsed 2. CAR-T Naive 3. Concurrent BTKi CAR T Naive and BTKi concurrent cohorts: Eligible patients with a CD19+ B-cell disease including DLBCL, HGBCL, FL (Grade1-3a), MZL, WM, PCNSL, MCL and CLL/SLL. Patients must have had at least 1-3 prior lines of therapy. The Recommended Phase 2 Regimen was determined to be: • 500M cells • Aug/Cy – Flu 30mg/m2 x 3 days, Cy 750mg/m2 x 3 days • Low-dose SC IL-2 (1 million IU, D1-14) 17 Cohort 2: CAR-T naïve patients show strong overall response rate in multiple indications Cohort 2 evaluates azer-cel in CAR-T naïve patients across rare and niche lymphomas RESULTS & KEY TAKEAWAYS 2026 American Society of Clinical Oncology (ASCO) oral presentation • Enrolling across multiple CD19+ B-cell malignancies including DLBCL, FL, CLL/SLL, MZL, WM and PCNSL • 24 Evaluable heavily pretreated CAR-T naïve patients Responses observed across all indications including; • 100% Overall Response Rate (ORR) in multiple indications including CLL/SLL, FL and WM • 83% ORR in MZL with 6/7 responders achieving a Complete Response (CR) or Partial Response (PR) • Fast Track Designation for CLL and MZL received in June, 2026 • No approved CAR-T therapies in several of these indications • Clear opportunity to expand into high-value niche populations *In CLL/SLL, complete responses are rare and partial responses have been sufficient to support regulatory approvals Overall (24)DLBCL/RT (6) MZL (6)CLL (4) PCNSL (4) FL (3) WM (1) 0 20 40 60 80 100 Indication (n, efficacy evaluable) PR CR Objective Response Rate (CR + PR), % 100% 100%100% 79% 67% 83% 50%42% 38% 50% 17% 67% 17% 75% 25% 67% 33% 18 Cohort 2: CAR-T Naïve Subset Indication On-going Responses In MZL & CLL/SLL 18 Drug Data (N=6 Evaluable) Comments Azer-cel ORR: 83%, CR: 67% mPFS and mDoR ongoing Zanubrutinib (BTKi) ORR: 68%, CR: 26%,mPFS: 70% @ 24mo (median not reached) Data in 3L+ (same line of therapy as azer-cel) Liso-cel (Auto CAR-T) ORR: 84%, CR: 56% mDoR Not reached Commercial uptake TBD (66 patient cohort) Drug Data (N=4 Evaluable) Comments Azer-cel ORR: 100% mPFS and mDoR ongoing Pirtobrutinib (BTKi) ORR: 69%, mPFS 14.1mo sBLA for 1L submitted Liso-cel (Auto CAR-T) ORR: 48%, mPFS: 11.9mo mDOR for PR: 23.8mo Overall Response Rate (ORR): the percentage of patients whose cancer shrinks or disappears after treatment. Complete Response (CR): disappearance of all detectable signs of cancer after treatment Partial Response (PR): Significant reduction in tumour size (typically at least 50%) or disease burden, but not complete disappearance EARLY DATA TRENDING FAVOURABLY IN COMPARISON TO OTHER TREATMENT OPTIONS 0 2 4 6 8 10 4002-006 4002-012 1062-021 4002-007 1001-003 1062-022 Months post CAR-T treatment MZL CLL 0 2 4 6 8 10 4002-008 4072-001 4002-005 4026-001 Months post CAR-T treatment UE SD PR CR PD Contuning Response • In CLL/SLL, CRs are uncommon and ORR (including PRs) has supported regulatory approvals (U.S. FDA guidance). • To be eligible for study, all CLL pts must have received a prior BTKi and BCL2i Median Progression Free Survival (mPFS): the median time patients live without their disease worsening Median Durability of Response (mDoR): the median time a treatment response lasts before the disease progresses. 19 BTKi Drug Annual Revenue Contribution Ibrutinib ~$4-6B Acalabrutinib ~$1-2B Zanubrutinib ~$1-2B Pirtobrutinib & others Several hundred million, expanding Total annual BTKi market1: USD ~$10-11.5B (2024-2025) and growing; Forecast to grow to USD 13.1B in 2026 Combination with existing BTKi’s to increase registrational and commercial opportunity • BTK inhibitors are an established standard of care across multiple B-cell malignancies with >US$10bn in annual global sales • Combining azer-cel with an approved BTKi has the potential to expand addressable patient populations beyond current CAR-T settings • Leverages an existing commercial drug class with significant physician adoption • BTKi are currently approved in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM) and other B-cell malignancies and auto immune diseases Cohort 3: BTKi Market is Large and Growing 1Global market for BTKi: GlobalData 18 Jan 2024, the Business Research Company, February 2026 20 Cohort 3: BTKi + azer-cel Concurrent Combination Combination Supports Expanded Registrational and Commercial Opportunity CLL = Chronic Lymphocytic Leukemia, MCL = Mantle Cell Lymphoma BTK inhibitors are an established standard of care across multiple B-cell malignancies and when combined with azer-cel, BTKis: • Enhance CAR-T cell fitness and durability, keeping T-cells younger, more energetic, and resistant to exhaustion over time1,2 • Improves the tumor microenvironment, making it less hostile and more supportive of sustained immune activity2,3 1Yao et al., ASH 2025, 2Luo et al., Cytotherapy (2023), 3Frost et al., ASH 2024, 4Minson et al., Blood (2024), 5Wierda et al., ASH (2024) Clinical evidence of synergy • 85% ORR / 80% CR – TARMAC Phase 2 Trial of Ibrutinib (BTKi) + CTL019 (CAR-T) in R/R MCL4 • 86% ORR / 45% CR (N=51) – TRANSCEND-CLL 004 Phase 1/2 Trial, Ibrutinib + Liso-cel (CAR-T) cohort5 First Two Evaluable Patients Achieved a Complete Response (CR) July 2026 21 Clinical • Continued enrollment and data maturation for: • CAR-T naïve/ niche cohorts • BTKi + azer-cel combination cohorts • Additional data presentation at ASCO, EHA, ASH 2026 Manufacturing & Supply • Scale-up and validation of registrational manufacturing • Readiness for one-to-many allogeneic supply model • Continue to align our CMC activity with FDA Regulatory • Continued FDA engagement to support: • Accelerated approval pathway • Label expansion into additional niche indications • FDA Fast Track Designation for DLBCL, MZL and CLL to de-risk development timeline Business Development • Advanced discussions on collaboration with Pharma • Partnering / out-licensing discussion for: • Azer-cel (regional or indication-specific) • BTKi combination strategy (major pharmaceutical blockbuster drug) 2026 Provides Opportunity to Progress Toward Registrational Strategy Proposed Clinical Pathway: Azer-cel Allogeneic CD19 CAR-T Phase 1b 2024+ Continue advancement of azer-cel across Cohorts 2 and 3: • Expansion into CAR-T naïve rare and niche indications • Advance BTKi + azer-cel combination and CAR-T naïve lymphoma cohorts to support expanded Registrational Path • Leverage FDA-aligned one randomized study supporting both accelerated approval and full approval Phase 1 2020- 2023 2026 Execution   Lymphoma & Leukaemia n=84 Auto CAR-T failed Lymphoma (3L+ DLBCL) Auto CAR-T naïve/niche Indications (e.g. PCNSL)  Successful FDA Type C End-of-Phase Meeting Q4 CY2025  >130 patients dosed to date 22 22 Capital Raising Overview 23 Capital Raising Summary Placement • Imugene has raised approximately A$11.1 million (before costs) via the issue of approximately 117.1 million fully paid ordinary shares in the Company (“New Shares”) at the Offer Price via a two-tranche placement (“Placement” or “Offer”) comprising: • Tranche 1 Placement to raise approximately $7.0 million (before costs) through the issuance of approximately 73.7 million New Shares utilising the Company’s available placement capacity under ASX Listing Rule 7.1 and 7.1A (“Tranche 1 Placement”); and • Tranche 2 Placement to raise up to approximately $4.1 million (before costs) through the issuance of up to approximately 43.4 million New Shares, subject to shareholder approval at an Extraordinary General Meeting (“EGM”) to be held on around Tuesday, 18 August 2026 under ASX Listing Rule 7.1 and 10.11 (“Tranche 2 Placement”) o Subject to shareholder approval, part of the Tranche 2 Placement includes a conditional Placement to Directors of Imugene to raise approximately $0.12 million (before costs) through the issuance of approximately 1.3 million New Shares (“Directors Placement”) Offer Price  The Offer price of A$0.095 per New Share (Offer Price), which represents a:  17.7% discount to the 30-day VWAP of A$0.115 per share  29.6% discount to the last closing price of A$0.135 per share as at Thursday, 2 July 2026 Ranking  New Shares issued under the Offer to rank equally with existing ordinary shares on issue in Imugene as at the date of issuance of the applicable New Shares Use of Funds and Pro-forma Cash  Funds will be used to advance azer-cel through critical clinical, regulatory and manufacturing milestones  At completion of the Offer the Company is expected to have a pro-forma cash position of A$17.8 million (before Offer costs), which funds the Company into CY2027 Lead Manager and Bookrunner  Bell Potter Securities Limited (Bell Potter) is acting as Bookrunner and Lead Manager to the Placement Two-tranche Placement of ~A$11.1 million to advance azer-cel through critical clinical, regulatory and manufacturing milestones 24 SOURCES OF FUNDS A$M Proforma Cash Balance as at 1 June 2026 4.8 R&D Tax Rebate 1.9 Offer Proceeds 11.1 Total Sources 17.8 USES OF FUNDS A$M Azer-cel 12.0 General & Administrative 5.1 Offer Costs 0.7 Total Uses 17.8 • Offer proceeds of ~A$11.1 million adds to the existing pro forma cash balance, including expected receipt of R&D rebate • Fund the continued clinical development of azer-cel, including expansion of Cohort 2 (CAR T-naïve) and Cohort 3 (BTKi combination) in the Phase 1b trial: • Advance regulatory engagement and planning to support the transition to a pivotal/registrational study. • Continue advanced discussions with major global pharmaceutical companies regarding potential strategic collaborations. • Progress ongoing partnering and out-licensing discussions for azer-cel • G&A costs represent significant cost saving efforts, with headcount reduced from 100 to ~13 but importantly, key management personnel retained. Raising proceeds to be used to continue the ongoing development of azer-cel through the expansion of Cohort 2 and the new Cohort 3 (BTKi) of its Phase 1b trial, funding the Company into CY2027 Sources & Uses 25 Indicative Timetable Event Date (2026) Trading Halt and bookbuild opens Friday, 3 July 2026 Announcement of Capital Raising and trading halt is lifted Tuesday, 7 July 2026 Settlement of New Shares Issued under the Tranche 1 Placement Friday, 10 July 2026 Allotment of New Shares issued under Tranche 1 of the Placement Monday, 13 July 2026 EGM to approve issue of New Shares under the Directors Placement and Tranche 2 Placement Expected on or around Tuesday, 18 August 2026 Settlement of New Shares issued under Tranche 2 of the Placement Expected on or around Friday, 21 August 2026 Allotment of New Shares issued under Tranche 2 of the Placement Expected on or around Monday, 24 August 2026 The above timetable is indicative only and subject to change. Subject to the requirements of the Corporations Act, the ASX Listing Rules and any other applicable laws, Imugene in consultation with the Lead Manager, reserves the right to amend the timetable and withdraw the Offer at any time. 26 Key Risk Factors Specific investment risks • IMU’s products in development and not approved for commercial sale – Investment in IMU should be considered speculative because of its commercialisation stage and that it has achieved sales revenue of any products. • Clinical trial risk - there is no assurance that products developed using the Company’s technology will prove to be safe and efficacious in clinical trials. Clinical trials could be terminated which will likely have a significant adverse affect on the Company, the value of its Securities and the future commercial development of its portfolio. • Regulatory and reimbursement approvals - Products developed using the Company’s technology must undergo a comprehensive and highly regulated development and review process before receiving approval for marketing. The process includes the provision of clinical data relating to the quality, safety and efficacy of the products for their proposed use. There is no guarantee regulatory approval will be obtained in relevant jurisdictions. Products may also be submitted for reimbursement approval. The availability and timing of that reimbursement approval may have an impact upon the uptake and profitability of products in some jurisdictions. • Commercialisation of products and potential market failure – The company’s products may prove difficult to manufacture on a large scale, uneconomical to market, unable to compete with products marketed by third parties or not be as attractive as alternative treatments. • Dependence upon key personnel – IMU depends on the talent and experience of its personnel as its primary asset. There may be a negative impact on Imugene if any of its key personnel leave. It may be difficult to replace them, or to do so in a timely manner or at comparable expense. • Arrangements with third-party collaborators - Imugene may pursue collaborative arrangements with pharmaceutical and life science companies, academic institutions or other partners to complete the development and commercialisation of its products. These collaborators may be asked to assist with funding or performing clinical trials, manufacturing, regulatory approvals or product marketing. There is no assurance that Imugene will attract and retain appropriate strategic partners or that any such collaborators will perform and meet commercialisation goals. If Imugene is unable to find a partner, it would be required to develop and commercialise potential products at its own expense. This may place significant demands on the Company’s internal resources and potentially delay the commercialisation of its products. • Risk of delay and continuity of operations - Imugene may experience delay in achieving a number of critical milestones, including securing commercial partners, completion of clinical trials, obtaining regulatory approvals, manufacturing, product launch and sales. Any material delays may impact adversely upon the Company, including the timing of any revenues under milestone or sales payments. Imugene may also experience business continuity problems arising from extreme events. As with most businesses, Imugene is reliant on IT systems in its day-to-day operations. An inability to operate such systems would impact the business. This might result, for example, from a computer virus or other cyber attack or from a physical event at its offices. • Competition - The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. A number of companies, both in Australia and abroad, are developing products that target the same markets that Imugene is targeting. • Requirement to raise additional funds - The Company may be required to raise additional equity or debt capital in the future. There is no assurance that it will be able to raise that capital when it is required or, even if available, the terms may be unsatisfactory. If the Company is unsuccessful in obtaining funds when they are required, the Company may need to delay or scale down its operations. • Growth - There is a risk that the Company may be unable to manage its future growth successfully. The ability to hire and retain skilled personnel as outlined above may be a significant obstacle to growth. • Intellectual property -The Company’s ability to leverage its innovation and expertise depends upon its ability to protect its intellectual property and any improvements to it. The intellectual property may not be capable of being legally protected, it may be the subject of unauthorised disclosure or be unlawfully infringed, or the Company may incur substantial costs in asserting or defending its intellectual property rights. 27 Key Risk Factors General investment risks • Investment risks - The price of the Shares might rise or fall and they might trade at prices below or above the Offer Price. There can also be no assurance that an active trading market will exist for the Shares. Factors affecting the price at which Imugene Shares are traded on ASX could include domestic and international economic conditions. In addition, the prices of a listed entity’s securities are affected by factors that might be unrelated to its operating performance, such as general market sentiment. • Macro economic risks - Imugene’s operating and financial performance is influenced by a variety of general economic and business conditions including the level of inflation, interest rates and government fiscal, monetary and regulatory policies. Prolonged deterioration in general economic conditions, including an increase in interest rates, could be expected to have a corresponding adverse impact on the Company’s operating and financial performance. • Taxation risks - Changes to the rate of taxes imposed on Imugene (including in overseas jurisdictions in which Imugene operates now or in the future) or tax legislation generally may affect Imugene and its Shareholders. In addition, an interpretation of Australian tax laws by the Australian Taxation Office that differs to Imugene’s interpretation may lead to an increase in Imugene’s tax liabilities and a reduction in Shareholder returns. Personal tax liabilities are the responsibility of each individual investor. Imugene is not responsible either for tax or tax penalties incurred by investors. • Accounting standards - Australian accounting standards are set by the Australian Accounting Standards Board (AASB) and are outside the Directors’ and Imugene’s control. Changes to accounting standards issued by AASB could materially adversely affect the financial performance and position reported in Imugene’s financial statements. • Litigation - There is a risk that the Company may in future be the subject of or required to commence litigation. There is, however, no litigation, mediation, conciliation or administrative proceeding taking place, pending or threatened against the Company. Cautionary statement • Statements in this Presentation may be forward looking statements. Forward looking statements can be identified by the use of forward-looking terminology such as, but not limited to, ‘may’, ‘will’, ‘expect’, ‘anticipate’, ‘estimate’, ‘would be’, ‘believe’, or ‘continue’ or the negative or other variations of comparable terminology. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. The Directors’ expectations, beliefs and projections are expressed in good faith and are believed to have a reasonable basis. They are based on, among other sources, the examination of historical operating trends, data in the Company’s records and other data available from third parties. There can be no assurance, however, that the Directors’ expectations, beliefs or projections will give the results projected in the forward-looking statements. Investors should not place undue reliance on these forward-looking statements. Additional factors that could cause actual results to differ materially from those indicated in the forward- looking statements are discussed earlier in this section. 28 Foreign Offer Restrictions This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this presentation, you should observe such restrictions as any non-compliance with these restrictions could contravene applicable securities laws (as set out below). Hong Kong WARNING: This presentation has not been, and will not be, registered under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong (the “SFO”). Accordingly, this presentation may not be distributed in Hong Kong other than to “professional investors” (as defined in the SFO and any rules made under that ordinance). No advertisement, invitation or document relating to information contained in this presentation has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than to professional investors. The contents of this presentation have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this presentation, you should obtain independent professional advice. New Zealand This presentation has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (the “FMC Act”). The information provided in this presentation does not constitute an offer to sell securities in New Zealand (or allotted with a view to being offered for sale in New Zealand) other than to a person who: 1. is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act; 2. meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act; 3. is large within the meaning of clause 39 of Schedule 1 of the FMC Act; 4. is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or 5. is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act. Singapore This presentation and any other materials relating to this presentation have not been, and will not be, lodged or registered in Singapore with the Monetary Authority of Singapore. Accordingly, this presentation and any other document or materials in connection with the offer or sale, or invitation for subscription or purchase, of securities, may not be issued, circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore except pursuant to and in accordance with exemptions in Subdivision (4) Division 1, Part 13 of the Securities and Futures Act 2001 of Singapore (the “SFA”) or another exemption under the SFA. This presentation has been given to you on the basis that you are an “institutional investor” or an “accredited investor” (as such terms are defined in the SFA). If you are not such an investor, please return this presentation immediately. You may not forward or circulate this presentation to any other person in Singapore. 29 29 ASX : IMU imugene.com Connect with us on LinkedIn @Imugene Limited Watch us on YouTube @ImugeneLimited

The release as fetched from its publisher. weblink.com.au ↗